Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138004 | 1.00 | HRH3 (0.46) | HRH3ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3138014 | 1.00 | HRH3 (0.46) | HRH3ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28248997 | 0.85 | HRH3 (0.46) | HRH3KCNH2L3MBTL1 | |
| SCHEMBL27638743 | 0.85 | SIGMAR1 (0.50) | HRH3ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29050285 | 0.85 | ALDH1A1 (0.44) | HRH3KCNH2 | |
| SCHEMBL10232715 | 0.80 | HRH3 (0.67) | HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL2723612 | 0.79 | HRH3 (0.65) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL27638820 | 0.78 | MITF (0.50) | HRH3KCNH2L3MBTL1HTR2AHTR2C | |
| SCHEMBL11789571 | 0.77 | SIGMAR1 (0.62) | HTR2C | |
| SCHEMBL5816124 | 0.77 | SIGMAR1 (0.62) | HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10351531-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170320831-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9732039-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmeceuticals, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9434692-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-03-17 | — | — | US | disclosed |
| CN-102838546-B | Pyrazole derivatives as modulators of 5-ht2a serotonin receptor useful for treatment of disorders related thereto | ARENA PHARM INC | 2015-07-15 | — | — | CN | disclosed |
| EP-2066641-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| CN-101611013-A | As 5-HT2APyrazole derivatives of serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2066641-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | HRH3 844/4885ACHE 796/4885SLC6A2 389/4885 |
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HRH3 830/4885ACHE 791/4885SLC6A2 341/4885 |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HRH3 864/4885ACHE 1200/4885SLC6A2 164/4885 |
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | HRH3 844/4885ACHE 796/4885SLC6A2 389/4885 |
| US-20170320831-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR3A | HRH3 794/4885ACHE 778/4885SLC6A2 383/4885 |
| US-10351531-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR2A, HTR3A | HRH3 794/4885ACHE 778/4885SLC6A2 383/4885 |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | HRH3 844/4885ACHE 796/4885SLC6A2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.